Juan Gabriel Juárez-Rojas was born in Mexico (Mexico City) in 1976, graduated in Biology from the National Autonomous University of Mexico (1996-2001), and Philosophy Doctor via School of Medicine at the same University (2007-2011). Juárez-Rojas Gabriel obtained an Honorable Mention in the examination for the degree of Doctor Science, and after that, he realized a postdoctoral fellowship in the Henry Ginsberg Lab at Columbia University between the dates of July 30, 2012 and July 31, 2013. During that time he analyzed the effects of a cellular chaperon, cyclophilin, on the secretion of apolipoprotein B, which is necessary for the assembly and secretion of VLDL and LDL, the main atherogenic lipoproteins. Some honors include Ignacio Chavez Award for Clinical Research Awarded by the Mexican Society of Cardiology in 2007, second place in the Clinic Area of the XX National Award for Clinical Research GlaxoSmithKline Foundation and Mexican Health Foundation in 2009, Partner Head of the Mexican Society of Nutrition and Endocrinology from 2008, and Member of the National System of Researchers from 2010, awarded by the National Council of Science and Technology. He has directed up to the moment 5 theses and has participated in 5 different grant supported projects. He has published 38 articles in national and international magazines, participated in three chapter books and presented almost 50 communications and posters in different national and international congresses. From 2000, when he arrived at National Institute of Cardiology Ignacio Chávez for Social Service, he has working as Laboratory Technician (2001-2006), Assistant Research (2006-2009), and Research in Medical Science (2009-now a day). He has been Head of Studies of the Endocrinology Department at National Institute of Cardiology, and now a day he participates in other Services from National Institute of Cardiology and other Mexican Hospitals.

Juan Gabriel Juárez-Rojas research interests are coronary heart disease and associated risk factors such as metabolic syndrome, obesity, inflammation, insulin resistance, diabetes, hepatic steatosis or dyslipidemia.